Sumathi Sivapalasingam

TL;DR: In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline.

TL;DR: In this article, the authors describe parallel efforts using both humanized mice and convalescent patients to generate antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, which yielded a large collection of fully human antibodies that were characterized for binding, neutralization and three-dimensional structure.

TL;DR: In this paper, the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-CoV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well as in preclinical in vitro studies using single, dual, or triple antibody combinations.

TL;DR: Suptavumab did not reduce overall RSV hospitalizations or outpatient LRTI because of a newly circulating mutant strain of RSV B and genetic variation in circulating RSV strains will continue to challenge prevention efforts.

TL;DR: Safety, tolerability, pharmacokinetics, and anti-drug antibodies in healthy adults investigating a co-formulated cocktail of three human monoclonal antibodies targeting three non-overlapping epitopes on Ebola virus support further clinical development of REGN3470-3471-3479 as a single-dose therapeutic drug for acute Ebola virus infection.